ACUT ACCUSTEM SCIENCES INC
- 0.388000
- 0.0000000.00%
ACCUSTEM SCIENCES INC News
AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly
AccuStem Sciences, Inc. Extends and Broadens Partnership With Instituto Europeo Di Oncologia (IEO) Enabling Its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem
Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc.
BALTIMORE, MD / ACCESSWIRE / June 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new re
AccuStem Sciences, Inc. Announces Collaboration Agreement With University Hospitals
AccuStem Sciences, Inc. (OTCQB: ACUT) today announced the establishment of a joint clinical collaboration agreement with University Hospitals.
AccuStem Announce Strategic Clinical and Operational Partnership
LONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today annou
AccuStem Sciences Announces Extension of Its US Patent Application for SPARE Test for Patients With Breast Cancer
LONDON and PHOENIX, May 02, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced t
Cancer Diagnostics Maker Accustem Files for Nasdaq Uplisting, $11M Offering
AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors
LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced
AccuStem Announces Adjournment of Annual Meeting of Stockholders
LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced t
AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients With Breast Cancer
LONDON and PHOENIX, Ariz., Sept. 13, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, an
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, April 28, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified
4 Stocks Under $2 Insiders Are Aggressively Buying
US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concer
AccuStem Announces Private Placement of Common Stock
LONDON and PHOENIX, April 05, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that it h
AccuStem Sciences, Inc. Announces DTC Eligibility
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to annou
Analysis
Price Target
No Data
